Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

You fall, and the pain in your leg confirms your worst fear — it's fractured. The nearest medical facility that can properly treat your injury is miles away, only accessible by air ambulance. It's ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

MANILA, Philippines — The Senate of the Philippines launched on Thursday in Tuguegarao City, Cagayan and Talisay City, Cebu the online platform “Senate Assist” that aims to bring medical and ...

NEW YORK – Merck on Thursday said it is discontinuing the Phase III KEYNOTE-630 trial of Keytruda (pembrolizumab) as adjuvant therapy in patients with high-risk, locally advanced cutaneous squamous ...

The Medical and Dental Council of Nigeria (MDCN) has declared that online medical schools are not recognised in Nigeria. The council affirmed that the practice of medicine requires in-person ...

The online register will be upgraded and augmented with continuous improvements in the registration process on the portal. Highlighting the role of the state medical councils (SMCs), Minister ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.